Vivet Therapeutics announces presentation on its lead product at the upcoming 2018 International Liver Congress, Paris April 14, 2018. Dr. Oihana Murillo-Sauca, researcher at the Fundación para la Investigación Médica Aplicada (FIMA) located at CIMA, a leading research center in the field of Gene Therapy located in Pamplona, Spain, will present recent preclinical data on Vivet’s lead product, VTX-801, generated in the context of a strategic collaboration between FIMA and Vivet. VTX-801 is an adeno-associated virus (AAV) containing a gene coding for a functional mini-ATP7B copper transporter, that is intended to restore copper homeostasis through liver cell targeting in Wilson’s Disease. The presentation (“Gene Therapy Optimization for Wilson´s Disease”) will take place during the “Clinical developments in metabolic and rare disease” session and will include data demonstrating that gene therapy using an optimized gene therapy vector (VTX 801) provides long term correction of copper metabolism. (West 3, 9:30-9:45 Paris April 14, 2018).
